At this year’s Society of Gynecologic Oncology Annual Meeting, we presented data that reinforced our goal to deliver solutions for people living with gynaecologic cancers, including endometrial and ovarian cancer. While we shared these scientific advances, I believe it’s important to recognise that progress must extend beyond treatment. Many patients still face barriers related to information, education, and comprehensive support that can impact their journey and quality of life. Your Cancer Is ...
Pedro Sánchez visits Spain's first high-biosecurity lab at GSK
Spanish PM Pedro Sánchez visited GSK's BSL-4 lab in Tres Cantos, the first of its kind in Spain and in a pharmaceutical company worldwide, investing €5.2M for infectious disease research.
Next-gen immunotherapies compete in multiple myeloma
Next-generation immunotherapies like Tecvayli, Carvykti and Blenrep are competing in relapsed/refractory multiple myeloma treatment. ASH 2025 highlighted impressive survival data for Tecvayli+Darzalex combination.
Clarivate identifies 11 transformative drugs for 2026
Clarivate's 2026 Drugs to Watch report highlights 11 therapies expected to significantly impact patient care and achieve commercial success in metabolic disease, oncology, immunology, rare conditions, and neurological disorders.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.
Get full access to view complete information
1 - 25 of 139
Get full access to view complete information
Frequently Asked Questions Regarding GSK
Company Overview
1998
Founded
Pharmaceutical Manufacturing
Industry
United Kingdom
Location
19,624
Ranking
98,100 employees
Size
Similar Companies
Get full access to view complete information
Frequently Asked Questions Regarding GSK
Start your journey today
Start with the platform — or start with a conversation
Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.